Yusefi Ali Reza, Mehralian Gholamhossein, Khodamoradi Abdolvahed, Abbasi Roghaye, Vatankhah Fatemeh, Heaidari Fatemeh, Bastani Peivand
Department of Public Health, School of Health, Jiroft University of Medical Sciences, Jiroft, Iran.
School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Cost Eff Resour Alloc. 2022 Mar 19;20(1):12. doi: 10.1186/s12962-022-00350-7.
Out-of-pocket (OOP) is among the payment methods in Iran's health system. The present study aimed to examine the OOP treatment costs for patients with COVID-19 in Iran.
A descriptive-analytical, cross-sectional study was conducted in 2021. In this study, the cost records of 550 patients with COVID-19 hospitalized in a referral center of COVID-19 were selected using the stratified random sampling method. The required data were collected using a researcher-made questionnaire. Data were analyzed by t-test, ANOVA, and Pearson's correlation coefficient in SPSS software version 23 at p = 0.05.
The total direct costs were 1,037,992.15 US $. Moreover, the shares of patients (OOP), basic insurance, government subsidy, supplementary insurance, discounts, and out-of-government subsidy in the total direct costs were US $ 92,231.21, 746,932.99 US $, 155,127.08 US $, 39,690.25 US $ and 4010.61 US $, respectively. In addition, the results confirmed that there was a positive and significant relationship between the patients' OOP payments and the length of stay. It also found that the patients' OOP payments are subject to the type of insurance program and discharge method.
According to the results, 8.89% of the total direct costs were directly paid out of the patients' pockets. The research findings confirm the urgent need to make decisions and implement effective interventions for COVID-19 disease by controlling risk factors and exploiting other countries' successful experiences and international organizations' recommendations to decrease the prevalence of the infected and consequently reduce the financial pressure of the disease on patients by approving the expansion of the insurance organizations' role.
自付费用是伊朗医疗系统的支付方式之一。本研究旨在调查伊朗新冠肺炎患者的自付治疗费用。
2021年进行了一项描述性分析横断面研究。在本研究中,采用分层随机抽样方法,选取了在一家新冠肺炎转诊中心住院的550例新冠肺炎患者的费用记录。所需数据通过研究者自制的问卷收集。在SPSS 23软件中,采用t检验、方差分析和Pearson相关系数对数据进行分析,p = 0.05。
总直接费用为1,037,992.15美元。此外,患者自付费用、基本保险、政府补贴、补充保险、折扣和政府外补贴在总直接费用中的占比分别为92,231.21美元、746,932.99美元、155,127.08美元、39,690.25美元和4,010.61美元。此外,结果证实患者的自付费用与住院时间之间存在正相关且具有显著性。研究还发现,患者的自付费用受保险计划类型和出院方式的影响。
根据研究结果,总直接费用的8.89%由患者直接自掏腰包支付。研究结果证实,迫切需要通过控制风险因素、借鉴其他国家的成功经验和国际组织的建议,对新冠肺炎疾病做出决策并实施有效干预措施,以降低感染率,从而通过扩大保险机构的作用来减轻疾病给患者带来的经济压力。